Dr. Haggerty is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Riverview Plaza
Red Bank, NJ 07701Phone+1 732-530-2410Fax+1 732-268-8474
Summary
- Dr. Ashley Haggerty is a board-certified Gynecologic Oncologist in New Jersey and an Associate Professor at the Hackensack Meridian Health School of Medicine. She is affiliated with multiple hospitals in the Hackensack Meridian Health system, including Riverview Medical Center and Jersey Shore University Medical Center. She received her residency training in Obstetrics and Gynecology and then fellowship in Gynecologic Oncology at the Hospital of the University of Pennsylvania. She was then faculty and an assistant professor at the Hospital of the University of Pennsylvania, and also held privileges at Children's Hospital of Philadelphia and Pennsylvania Hospital. She received her medical degree from Wake Forest School of Medicine of Wake Forest Baptist Medical Center and also completed a Masters in Clinical Epidemiology from the University of Pennsylvania. She has been in practice for 10 years. She specializes in the surgical and medical management of gynecologic oncology and is experienced in hereditary ovarian cancer, gynecologic cancer, minimally invasive gynecologic surgery, and robotic surgery.
Education & Training
- University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2012 - 2015
- University of PennsylvaniaMSCE, 2012 - 2014
- University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 2008 - 2012
- Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2008, MD
- Yale UniversityBA, 2000 - 2004
Certifications & Licensure
- NJ State Medical License 2022 - 2025
- PA State Medical License 2013 - 2024
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis Start of enrollment: 2016 Jan 01
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Start of enrollment: 2019 Mar 06
Publications & Presentations
PubMed
- Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley
Journal of Comparative Effectiveness Research. 2025-01-01 - "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.Anna Jo Bodurtha Smith, Caroline O'Brien, Ashley Haggerty, Emily M Ko, Katharine A Rendle
Gynecologic Oncology. 2024-07-01 - 1 citationsElectronic medical record documentation of germline genetic evaluations in patients with ovarian cancer.Melissa Batson, Lindsay G Goldblatt, Stacy Pundock, Anna Arutyunov, Danielle McKenna
Journal of Genetic Counseling. 2024-04-01
Press Mentions
- What’s the Difference Between an Ovarian Cyst and Ovarian Cancer?August 28th, 2019
Professional Memberships
- Member
- Society of Gynecologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: